Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications

Gail Schwartz, Robert Platt

Research output: Contribution to journalReview article

Abstract

Investigators have developed methods to estimate the number of healthy days or symptom-free days in randomized trials or population-based settings. Such measures can be used in cost-effectiveness studies or disease management surveillance. This paper suggests that the concept can be extended to measure intraocular pressure (IOP)-controlled days in glaucoma by combining data from randomized trials on IOP control (ie, whether a target IOP or percent reduction in IOP was achieved) with data from pharmacy database studies on drug persistency. Patients with lower rates of persistency would be expected to experience fewer IOP-controlled days as they switch therapies or discontinue topical therapy altogether. Evaluating IOP-controlled days according to patients' topical glaucoma therapies could improve population-based disease management compared with the use of simpler measures that consider IOP measurements at a single point in time.

Original languageEnglish (US)
JournalAmerican Journal of Managed Care
Volume8
Issue number10 SUPPL.
StatePublished - Aug 1 2002
Externally publishedYes

Fingerprint

Intraocular Pressure
Glaucoma
medication
Disease
management
Disease Management
surveillance
drug
Cost of Illness
costs
experience
Population
Cost-Benefit Analysis
Therapeutics
Research Personnel
Databases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine(all)
  • Health(social science)
  • Health Professions(all)

Cite this

Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications. / Schwartz, Gail; Platt, Robert.

In: American Journal of Managed Care, Vol. 8, No. 10 SUPPL., 01.08.2002.

Research output: Contribution to journalReview article

@article{610262d53d3a4942b69573b0c8e18c78,
title = "Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications",
abstract = "Investigators have developed methods to estimate the number of healthy days or symptom-free days in randomized trials or population-based settings. Such measures can be used in cost-effectiveness studies or disease management surveillance. This paper suggests that the concept can be extended to measure intraocular pressure (IOP)-controlled days in glaucoma by combining data from randomized trials on IOP control (ie, whether a target IOP or percent reduction in IOP was achieved) with data from pharmacy database studies on drug persistency. Patients with lower rates of persistency would be expected to experience fewer IOP-controlled days as they switch therapies or discontinue topical therapy altogether. Evaluating IOP-controlled days according to patients' topical glaucoma therapies could improve population-based disease management compared with the use of simpler measures that consider IOP measurements at a single point in time.",
author = "Gail Schwartz and Robert Platt",
year = "2002",
month = "8",
day = "1",
language = "English (US)",
volume = "8",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "10 SUPPL.",

}

TY - JOUR

T1 - Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications

AU - Schwartz, Gail

AU - Platt, Robert

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Investigators have developed methods to estimate the number of healthy days or symptom-free days in randomized trials or population-based settings. Such measures can be used in cost-effectiveness studies or disease management surveillance. This paper suggests that the concept can be extended to measure intraocular pressure (IOP)-controlled days in glaucoma by combining data from randomized trials on IOP control (ie, whether a target IOP or percent reduction in IOP was achieved) with data from pharmacy database studies on drug persistency. Patients with lower rates of persistency would be expected to experience fewer IOP-controlled days as they switch therapies or discontinue topical therapy altogether. Evaluating IOP-controlled days according to patients' topical glaucoma therapies could improve population-based disease management compared with the use of simpler measures that consider IOP measurements at a single point in time.

AB - Investigators have developed methods to estimate the number of healthy days or symptom-free days in randomized trials or population-based settings. Such measures can be used in cost-effectiveness studies or disease management surveillance. This paper suggests that the concept can be extended to measure intraocular pressure (IOP)-controlled days in glaucoma by combining data from randomized trials on IOP control (ie, whether a target IOP or percent reduction in IOP was achieved) with data from pharmacy database studies on drug persistency. Patients with lower rates of persistency would be expected to experience fewer IOP-controlled days as they switch therapies or discontinue topical therapy altogether. Evaluating IOP-controlled days according to patients' topical glaucoma therapies could improve population-based disease management compared with the use of simpler measures that consider IOP measurements at a single point in time.

UR - http://www.scopus.com/inward/record.url?scp=0036679463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036679463&partnerID=8YFLogxK

M3 - Review article

C2 - 12188171

AN - SCOPUS:0036679463

VL - 8

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 10 SUPPL.

ER -